Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
January 08 2019 - 1:00PM
Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage
biopharmaceutical company focused on developing novel cell and gene
therapies for life-threatening rare genetic diseases, today
announced that it has appointed Christine Silverstein to the
position of Chief Financial Officer and named Edward Carr as Chief
Accounting Officer.
"Christine is a thoughtful and strategic leader
who is truly passionate about our Company's commitment to serve
patients and shareholders alike. Her healthcare and in-depth
capital markets experience has been instrumental in the
implementation of Abeona’s financial and operational strategy and
will play a vital role in our ability to generate higher growth and
enhance shareholder value,” commented João Siffert, M.D., Interim
Chief Executive Officer of Abeona. “Ed has considerable financial
and accounting experience and, in the short period since joining
Abeona, has implemented important financial practices that yielded
efficiencies and further strengthened our operations. Together,
Christine and Ed’s appointments round out our internal capabilities
that are imperative to our success.”
Ms. Silverstein was previously Senior Vice President, Finance
and Investor Relations for Abeona. Prior to joining Abeona in
2016, she served as Head of Investor Relations at Relmada
Therapeutics, Inc. a clinical stage specialty pharmaceutical
company. This was preceded by her role as Managing Director at SCO
Financial Group, where she drove strategy on capital formation and
business development opportunities for portfolio companies.
Ms. Silverstein began her career as an investment advisor at Royal
Alliance Associates, Inc. before leading teams at corporate
advisory firms, The Investor Relations Group and Corporate Profile,
LLC. She is a member of the National Investor Relations
Institute and holds a B.S. from the Peter Tobin College of
Business, St. John's University.
Prior to Abeona, Mr. Carr most recently served as Vice President
and Assistant Controller at Coty Inc., a publicly listed
multinational company. Prior to Coty, he served for more than
10 years as Chief Accounting Officer at Foster Wheeler AG, which
was preceded by his tenure at Ernst & Young LLP. He is a
Certified Public Accountant and holds a B.S. and Master of
Professional Accountancy from West Virginia University.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for life-threatening
rare genetic diseases. Abeona's lead programs include EB-101, its
gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa, and ABO-102, a novel AAV9 based gene therapy for
Sanfilippo syndrome type A (MPS IIIA). The Company’s portfolio of
AAV9 based gene therapies also features ABO-101 for Sanfilippo
syndrome type B (MPS IIIB), and ABO-201 and ABO-202 for CLN3
disease and CLN1 disease, respectively. Its preclinical assets
include ABO-401, which uses a novel AIM™ AAV vector platform to
address all mutations of cystic fibrosis. Abeona has received
numerous regulatory designations from the FDA and EMA for its
pipeline candidates and is the only company with Regenerative
Medicine Advanced Therapy designation for two investigational
therapies (EB-101 and ABO-102). For more information, visit
www.abeonatherapeutics.com.
Forward Looking Statements:
This press release contains certain statements that are
forward-looking within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and that involve risks and
uncertainties. These statements include statements about the
ability of its management team to lead the Company and deliver on
key strategies, the market opportunities for the Company’s products
and product candidates, and the Company’s goals and
objectives. We have attempted to identify forward looking
statements by such terminology as “may,” “will,” “anticipate,”
“believe,” “estimate,” “expect,” “intend,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to
identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, numerous risks and
uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in
clinical trials, the impact of competition, the ability to secure
licenses for any technology that may be necessary to commercialize
our products, the ability to achieve or obtain necessary regulatory
approvals, the impact of changes in the financial markets and
global economic conditions, risks associated with data analysis and
reporting, and other risks as may be detailed from time to time in
the Company’s Annual Reports on Form 10-K and quarterly reports on
Form 10-Q and other reports filed by the Company with the
Securities and Exchange Commission. The Company undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this presentation, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Investor Contact:Sofia WarnerDirector, Investor
RelationsAbeona Therapeutics Inc.+1 (646)
813-4710swarner@abeonatherapeutics.com
Media Contact:Scott SantiamoDirector, Corporate
CommunicationsAbeona Therapeutics Inc.+1 (718)
344-5843ssantiamo@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Oct 2023 to Oct 2024